Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
regorafenib + PD-1 antibody
- Development stage
- Phase 2
- Lead developer
- Sun Yat-sen University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
regorafenib + PD-1 antibody is an investigational combination therapy being evaluated by Sun Yat-sen University for the treatment of metastatic colorectal cancer, particularly in patients with microsatellite stable (MSS) or mismatch repair proficient (pMMR) tumors. This regimen combines regorafenib, a small-molecule multi-kinase inhibitor that targets pathways involved in angiogenesis (VEGFR1-3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), and the tumor microenvironment (PDGFR, FGFR, CSF1R), with a PD-1 checkpoint inhibitor. The PD-1 antibody component (such as nivolumab or toripalimab) blocks the interaction between the PD-1 receptor on T cells and its ligands, thereby enhancing the immune system's ability to identify and destroy cancer cells. Clinical trials at Sun Yat-sen University have also explored the addition of radiotherapy to this combination to potentially synergize with the immunotherapy and improve objective response rates in previously treated patients.
- Other names
- regorafenib and PD-1 antibodyregorafenib plus PD-1 inhibitorREGONIVO
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)BRAF (B-Raf proto-oncogene, serine/threonine kinase)CSF1R (Macrophage colony-stimulating factor receptor)DDR2 (Discoidin domain receptor tyrosine kinase 2)EPHA2 (Ephrin type-A receptor 2)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)MAPK14 (p38 mitogen-activated protein kinase alpha)NTRK1 (Tropomyosin-related receptor kinase A)PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)TEK (Tie2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on regorafenib + PD-1 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on regorafenib + PD-1 antibody.